Aventis exits JV with Novartis

14 Dec 2010 Evaluate

Aventis Pharma, the Indian arm of French multinational drug maker Sanofi-Aventis, will sell its 49 per cent stake in vaccine manufacturing unit, Chiron Behring Vaccines, to its joint venture partner Novartis Vaccines and Diagnostics for $ 22.4 million (Rs 101 crore).

The deal between the multinational drug firms would draw curtains to a two-year-old battle in India over rights to India's largest selling anti-rabies vaccine, Rabipur. It had sales of close to Rs 118 crore two years ago with a market share of about 70 per cent. The brand belongs to Chiron Behring Vaccines. Novartis had objected to the renewal of a 10-year marketing licence to Aventis Pharma last February.Until February 2009, Aventis manufactured Rabipur at its plant in Ankleshwar in Gujarat, while Novartis Healthcare was the distributor of the vaccines in the country.

After losing the rights of Rabipur, Aventis Pharma's arm, Shanta Biotech, launched group company Sanofi Pasteur's brand Verorab in the Indian market. This was challenged by Novartis in the Bombay High Court, citing conflict of interest. The court allowed the petition and Aventis is appealing the decision. India’s anti-rabies market is estimated to have an annual size of Rs 250 crore.crackcrack

Sanofi India Share Price

6011.35 11.40 (0.19%)
04-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1709.40
Dr. Reddys Lab 1109.75
Cipla 1415.55
Lupin 1971.10
Zydus Lifesciences 866.65
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...